Lytham Partners’ Robert Blum speaks with InMed Pharmaceuticals CEO, Eric A. Adams, and BayMedica’s VP Commercial Operations, Chris Meiering.
In this video, Eric and Chris talk about addressing the growing demand for rare cannabinoids, the company’s rare cannabinoid pharmaceutical programs and its multiple cannabinoid manufacturing approaches, such as biosynthesis, chemical synthesis and proprietary approach IntegraSyn, that can be used to produce different rare cannabinoids.
BayMedica has launched rare cannabinoid, cannabichromene (CBC), and was able to manufacture from benchtop to commercial scale for B2B sales as cannabinoid ingredients for the health and wellness market. Eric and Chris also talk about trends in rare cannabinoids for the health and wellness sector and what is being developed and launched by InMed and BayMedica.
